Trinity Biotech (TRIB) Receivables - Net (2014 - 2025)

Trinity Biotech (TRIB) has reported Receivables - Net for 12 consecutive years, with $43.8 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Net rose 4196.86% year-over-year to $43.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $43.8 million (up 4196.86% YoY) and the FY2025 annual result came in at $43.8 million, down 28.87% from the prior year.
• Receivables - Net climbed to $43.8 million in Q4 2025 per TRIB's latest filing, from $10.9 million in the prior quarter.
• Over the last five years, Receivables - Net for TRIB reached as high as $2.7 billion in Q4 2022 and fell as low as $1.0 million in Q4 2024.
• A 5-year average of $348.0 million and a median of $13.4 million in 2022 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net surged 90020.56% — and 2023, when it tumbled 99.95%.
• Year by year, Receivables - Net stood at $3.0 million in 2021, then jumped by 90020.56% to $2.7 billion in 2022, then slumped by 99.95% to $1.3 million in 2023, then fell by 22.15% to $1.0 million in 2024, then soared by 4196.86% to $43.8 million in 2025.
• According to Business Quant data, Receivables - Net over the past three periods registered $43.8 million, $10.9 million, and $1.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.